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Type I IFN Induces IL-10 Production in an IL-27–Independent
Manner and Blocks Responsiveness to IFN-g for Production
of IL-12 and Bacterial Killing in Mycobacterium
tuberculosis–Infected Macrophages
Finlay W. McNab,*,1 John Ewbank,*,1 Ashleigh Howes,* Lucia Moreira-Teixeira,*,†,‡
Anna Martirosyan,* Nico Ghilardi,x Margarida Saraiva,†,‡ and Anne O’Garra*
Tuberculosis, caused by the intracellular bacteriumMycobacterium tuberculosis, currently causes∼1.4 million deaths per year, and
it therefore remains a leading global health problem. The immune response during tuberculosis remains incompletely understood,
particularly regarding immune factors that are harmful rather than protective to the host. Overproduction of the type I IFN
family of cytokines is associated with exacerbated tuberculosis in both mouse models and in humans, although the mechanisms by
which type I IFN promotes disease are not well understood. We have investigated the effect of type I IFN on M. tuberculosis–
infected macrophages and found that production of host-protective cytokines such as TNF-a, IL-12, and IL-1b is inhibited by
exogenous type I IFN, whereas production of immunosuppressive IL-10 is promoted in an IL-27–independent manner. Further-
more, much of the ability of type I IFN to inhibit cytokine production was mediated by IL-10. Additionally, type I IFN compro-
mised macrophage activation by the lymphoid immune response through severely disrupting responsiveness to IFN-g, including
M. tuberculosis killing. These findings describe important mechanisms by which type I IFN inhibits the immune response during
tuberculosis. The Journal of Immunology, 2014, 193: 000–000.
M
yeloid cells such as macrophages are the predominant
targets of Mycobacterium tuberculosis infection (1–3).
Effector functions elicited in these cells upon infection
are crucial to the establishment of an adaptive immune response to
M. tuberculosis, restriction of bacterial growth, and ultimately to
host resistance (1–3). Key effectors linked to host protection
produced by these cells include the cytokines IL-12, TNF-a, and
IL-1a/b (1–3). Production of NO and other molecules that restrict
intracellular bacterial growth is also of importance (4–6). IL-12 is
critical for activation of CD4+ T cells, leading to the protective
Th1 response and induction of IFN-g from a variety of cellular
sources (7, 8). IFN-g is in turn crucial for the full activation of
macrophage bactericidal functions (such as NO production and
restriction of mycobacterial growth) and further enhancement of
innate cytokine production (5, 6, 9–14).
Whereas immune mechanisms that lead to host resistance have
been intensively studied, less is understood about potentially
damaging or inhibitory immune responses leading to activation or
exacerbation of tuberculosis (TB). There is a growing appreciation
that the type I IFN family of cytokines plays a detrimental as
opposed to protective role during TB, particularly when such
cytokines are present in excess amounts, with evidence in both
mice and humans largely supporting this hypothesis (15–25).
Studies of M. tuberculosis infection of mice that lack the receptor
common to all type I IFN (Ifnar12/2 mice) found reduced bac-
terial load and/or increased survival compared with wild-type
(WT) mice (18, 19, 22, 24), pointing to a negative role of type I
IFN in TB. However, results have not been unequivocal, with
some suggestion that type I IFN may have protective activities
under certain conditions (26, 27).
Studies where excess levels of type I IFN are induced during TB,
either through direct instillation of IFN-a/b into the lung (18),
administration of a polyinosinic-polycytidylic acid derivative (15),
or abrogation of a negative regulator of type I IFN signaling (28)
support a detrimental role for type I IFN during TB, as they all
resulted in exacerbated disease. In accordance with these results,
hypervirulent M. tuberculosis strains reportedly induce high levels
of type I IFN (18, 19).
Recent reports have also revealed a potential role for type I IFN
in the human immune response during TB, because cohorts of
active TB patients in London and South Africa showed a prominent
type I IFN–inducible gene signature in their blood, which cell
separation experiments found was present predominantly in my-
eloid cells (16). Furthermore, the signature was correlated with the
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extent of radiographic disease and resolved upon successful treat-
ment (16). These findings have now been verified by other groups
using patient cohorts from Africa (17, 29) and Indonesia (23).
The mechanisms by which type I IFN exacerbates disease during
M. tuberculosis infection are only partially understood. Recently,
studies have described a role for type I IFN in suppressing pro-
duction of the protective cytokine IL-1 in both in vivo mouse
models (20) and human monocytes (21). This inhibition of IL-1 was
partially dependent on IL-10 (20), which is known to be induced by
type I IFN (30–32). IL-10 is also induced during infection with
another intracellular bacteria, Listeria monocytogenes, where type I
IFNs are similarly detrimental to the host (33–36). Furthermore,
IL-10 is known to inhibit the immune response during TB, partic-
ularly the Th1 cell response (37–41). Earlier studies of infection
with hypervirulent M. tuberculosis strains that induce high levels of
type I IFN also point to a reduction in the protective Th1 response,
with reduced IL-12 and IFN-g during infection (18). In human
infections with the leprosy agent Mycobacterium leprae, type I IFN
has also been shown to induce IL-10 and restrict IFN-g–mediated
antibacterial responses (42). Additionally, type I IFNs have been
shown to downregulate IFN-g receptor expression on myeloid cells
during L. monocytogenes infection (43).
We have investigated the effects of type I IFN on macrophage
function during M. tuberculosis infection. We found that type
I IFN inhibits production of multiple protective cytokines by
M. tuberculosis–infected macrophages and induces the immuno-
suppressive cytokine IL-10. Notably, type I IFN also robustly
suppressed macrophage responsiveness to IFN-g, preventing IFN-g–
dependent enhancement of cytokine production and inhibiting
IFN-g–mediated macrophage bacterial growth inhibition and
killing. These results suggest an important role for type I IFN in
inhibiting the immune response to M. tuberculosis at the level of
the macrophage, potentially impairing both macrophage induction
of, and response to, adaptive immunity.
Materials and Methods
Mice
C57BL/6 (B6), B6 Ifnar12/2, B6 Il102/2, and B6 Tccr2/2 (IL-27R
a-chain–deficient) mice were bred and housed under specific pathogen-
free conditions at the Medical Research Council National Institute for
Medical Research, B6 Nos22/2 mice (and B6 WT controls) were bred and
housed under specific pathogen-free conditions at the Instituto de Biologia
Molecular e Celular (Porto, Portugal), and bones from these mice were
shipped overnight on ice to the National Institute for Medical Research.
All protocols for breeding and experiments were performed in accordance
with either Home Office (U.K.) requirements and the Animal Scientific
Procedures Act, 1986 or according to the European Union directive
86/609/EEC and approved by the Portugese national authority for animal
health, Direcc¸a˜o Geral de Veterina´ria (Portugal). Mice were sex and age
matched for use in experiments.
Reagents
Cell culture medium was RPMI 1640 (Lonza) supplemented with 5% heat-
inactivated FCS (Biosera), 0.05 mM 2-ME (Sigma-Aldrich), 2 mM
L-glutamine (Lonza), 1 mM sodium pyruvate (Lonza), and 10 mM HEPES
(Lonza). rIFN-b was purchased from PBL Assay Science and rIFN-g was
purchased from R&D Systems. IFN-b was used at 2 ng/ml unless other-
wise indicated, and IFN-g was used at 5 ng/ml. Anti–IL-10R (clone
1B1.3A) and anti–IL-10 (clone TC40.11D8) mAbs and their isotype
controls (GL113 and TC31.2F11, respectively) were gifts from DNAX
Research Institute (now Merck, Palo Alto, CA) and were used at 10 mg/ml.
Generation and infection of murine bone marrow–derived
macrophages and enrichment and infection of bone marrow
and lung myeloid cells
Bone marrow (BM) cells were flushed from the femurs and tibias of mice
and plated at 0.5 3 106 cells/ml on bacterial plates (Sterilin) in culture
medium containing 10% FCS and 20% L929 cell–conditioned medium. At
day 6, macrophages were harvested and seeded into 24-well tissue culture
plates (Corning) at 1 3 106 cells/ml. Cells were rested overnight, washed
once with PBS, and infected at a multiplicity of infection of 2:1 with
M. tuberculosis H37Rv and treated where indicated with recombinant
cytokines and/or mAbs. All experiments using M. tuberculosis were car-
ried out under biosafety containment level 3 conditions. M. tuberculosis
H37Rv was grown as previously described (39).M. tuberculosis was left in
the wells until the supernatant or cells were harvested, unless otherwise
stated. The number of bacteria in the inoculum was determined by serial
dilutions on 7H11 plates supplemented with 10% OADC. For mRNA
stability experiments cells were treated at 1 h after M. tuberculosis in-
fection with 10 mg/ml actinomycin D (ActD) and then harvested for RNA
at indicated time points after ActD treatment.
BM and lung myeloid cells were enriched from whole-organ cell sus-
pensions using EasySep (StemCell Technologies) magnetic separation
protocols. Cell suspensions were first enriched using the mouse monocyte
enrichment kit (StemCell Technologies, catalog no. 19761A), followed by
staining with anti-Ly6c FITC Ab (BD Pharmingen, clone AL-21) and
further enrichment with the mouse FITC selection kit (StemCell Tech-
nologies, catalog no. 18515). Cells were then plated at 0.5 3 106 cells/ml
and infected with H37Rv at a multiplicity of infection of 2:1 and treated
where indicated with rIFN-b and/or rIFN-g.
Enumeration of intracellular M. tuberculosis in macrophages
following infection
To determine the number of intracellular M. tuberculosis CFUs present in
macrophages following infection, supernatants were harvested, macro-
phages were washed once with PBS to remove extracellular bacteria, and 1
ml 0.2% saponin (Sigma-Aldrich) was added for 1 h at 37˚C to lyse the
cells. This suspension was then serially diluted and plated onto 7H11
plates supplemented with OADC, and colonies were counted after 14–
16 d at 37˚C.
Cytokine quantification by ELISA and bead array
Cytokine concentrations in the supernatants of infected cells were deter-
mined by ELISA or Luminex bead array at 24 h after M. tuberculosis
infection. This time point was chosen based on pilot experiments to de-
termine the optimal postinfection time point for analysis. Commercially
available kits were used for TNF-a, IL-12p70, IL-27 (all eBioscience), and
IL-1b (R&D Systems) and were used according to the manufacturers’
instructions. Matched Ab pairs were used for IL-12p40 and IL-10.
IL-12p40 was detected using Ab clone C15.6.7 for capture and bio-
tinylated Ab clone C17.8 for detection. IL-10 was detected using Ab clone
JES5-2A5 for capture and biotinylated anti–IL-10 for detection (BD
Biosciences, clone SXC-1). Custom magnetic bead arrays to measure
cytokines in supernatant of primary ex vivo cells were purchased from
Millipore (Merck Millipore, Billerica, MA) and used according to the
manufacturer’s instructions. Samples were run on a Bio-Rad Luminex 200
machine (Bio-Rad, Hercules, CA). Cytokine levels from uninfected cells
were below the assay level of detection unless otherwise shown (20 pg/ml
for ELISA, 5 pg/ml for bead array) (data not shown).
Processing of macrophage RNA and quantitative PCR analysis
At indicated times postinfection, supernatants were removed and cells
were washed once with PBS. RNA was harvested in 350 ml RLT buffer
(Qiagen) and stored at 280˚C before processing. RNAwas processed using
RNeasy Mini kits (Qiagen). RNA was reverse transcribed with a high-
capacity reverse transcription kit (Applied Biosystems) to cDNA. The ex-
pression of indicated genes was quantified by real-time PCR (ABI Prism
7900 from Applied Biosystems) and normalized against Hprt mRNA levels.
Murine primers were all purchased from Applied Biosystems.
Protein analysis and Western blotting
Spleens were homogenized by passing through a 70-mm sieve, and cell
suspensions were then RBC lysed and cultured in media containing 1%
FCS for 5 h before treatment with rIL-27 (50 ng/ml), rIFN-g (10 ng/ml), or
rIL-10 (10 ng/ml) for the indicated times. Where indicated cells were
treated with 200 ng/ml Pam3CSK4 (Invivogen). BM-derived macrophages
(BMDMs) were grown as described above but rested overnight in 1% FCS
prior to treatment with recombinant cytokines and stimuli, as indicated. Cells
were then harvested, lysed in RIPA buffer, and immunoblotting was carried
out as previously described (44). Anti–phospho-STAT1 (Y701), anti–total
STAT1, anti–phospho-STAT3 (Y705), anti–total STAT3 (all Cell Signaling
Technology), and anti-actin (Calbiochem) primary Abs, followed by HRP-
conjugated goat anti-rabbit IgG (SouthernBiotech) or goat anti-mouse IgM
(Calbiochem) secondary Abs, were used to probe membranes.
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Statistical analysis
Statistical analysis was carried out using Prism software version 6
(GraphPad Software). Statistical tests used to determine significance are
described in the figure legends with values as follows: *p , 0.05, **p ,
0.01, and ***p , 0.001.
Results
Type I IFN regulates IL-10 production in M. tuberculosis–
infected macrophages
Although type I IFN has been implicated in exacerbation of TB, it
remains unclear how it manifests its effects at the molecular level.
We investigated whether type I IFN regulated production of IL-10,
an immunosuppressive cytokine generally linked to TB exacer-
bation (37–41). Initially, we assessed whether type I IFN could
enhance IL-10 production by infecting WT macrophages with
M. tuberculosis and concomitantly adding rIFN-b at varying con-
centrations from 0.02 to 20 ng/ml (Fig. 1A). Addition of IFN-b
significantly enhanced IL-10 production by M. tuberculosis–
infected macrophages when added at 2 and 20 ng/ml (Fig. 1A).
Notably, type I IFN on its own was not sufficient to induce IL-10
production by macrophages, in support of a role for this cytokine
as an enhancer of IL-10 production (Fig. 1A). Additionally, we
assessed the effects of IFN-b addition on Il10 mRNA transcription
(Fig. 1B). Addition of 2 ng/ml IFN-b to M. tuberculosis–infected
macrophages resulted in enhanced Il10 mRNA levels at 6 h
postinfection (Fig. 1B).
We also investigated the effect of autocrine type I IFN on
macrophage IL-10 production in response to M. tuberculosis by
infecting WT and Ifnar12/2 macrophages with M. tuberculosis
H37Rv (Fig. 1C). Ifnar12/2 macrophages produced significantly
less IL-10 protein compared with WT macrophages following
M. tuberculosis infection (Fig. 1C), and Il10 mRNA transcription
was greatly reduced at 1 and 6 h postinfection in the Ifnar12/2mac-
rophages (Fig. 1D). We then examined myeloid cells taken directly
ex vivo from lungs and BM of mice for their ability to produce IL-
10 following M. tuberculosis infection and IFN-b treatment
(Fig. 1E). As with BMDMs, IFN-b increased the levels of IL-10
produced by M. tuberculosis–infected ex vivo myeloid cells from
lung (Fig. 1Ei) and BM (Fig. 1Eii). Thus, our data support a role
for type I IFN signaling in inducing IL-10 production by M. tu-
berculosis–infected macrophages, likely through transcriptional
regulation. Addition of IFN-b to M. tuberculosis–infected macro-
phages led to stable Il10 mRNA between 1 and 6 h (Fig. 1B),
suggestive of some effect on mRNA stability. To investigate this
further we performed experiments to assess Il10 mRNA stability
in the presence or absence of type I IFN signaling (Fig. 1F). WT
macrophages, with or without addition of rIFN-b, and Ifnar12/2
macrophages were infected with M. tuberculosis and 1 h after in-
fection ActD was added to the cultures to inhibit further tran-
scription. Il10 mRNA was then measured at 0, 30, 60, and 90 min
after ActD addition and plotted as a percentage of the Il10 mRNA
level in the 0 min ActD-treated samples (Fig. 1F). Loss of type I
IFN signaling did not greatly affect the decay of Il10 mRNA levels
over time, as WT and Ifnar12/2 macrophages had a similar per-
centage of Il10 mRNA over time after ActD treatment (Fig. 1F).
However, addition of rIFN-b to infected WT macrophages in-
creased Il10 mRNA stability, as the percentage of Il10 mRNA
remaining in IFN-b–treated macrophages was significantly in-
creased compared with M. tuberculosis–infected WT macrophages
alone and Ifnar12/2 macrophages (Fig. 1F). Thus, type I IFN
increases Il10 mRNA stability but is not absolutely required for
Il10 mRNA stability. Taken together, these data suggest that type I
IFN likely regulates IL-10 levels through a combination of tran-
scriptional control and modulation of Il10 mRNA stability.
IL-10 production, as well as enhancement of IL-10 production
by type I IFN, is independent of IL-27 signaling in
M. tuberculosis–infected macrophages
IL-27 is known to induce IL-10 production by T cells (45–47) and
has been suggested to act as an intermediate between LPS-induced
type I IFN and IL-10 production by macrophages (32). However,
in human monocytes (48) and some dendritic cells (49) it has been
reported that IL-27 inhibits IL-10 production. Furthermore, it has
been suggested that murine BMDMs are minimally responsive to
IL-27 (48). We therefore investigated a role for IL-27 in IL-10 in-
duction by type I IFN during M. tuberculosis infection of macro-
phages. Initially we determined whether type I IFN was required for
IL-27 production by M. tuberculosis–infected macrophages. Addi-
tion of IFN-b to WT macrophages upon M. tuberculosis infection
led to enhanced IL-27 production (Fig. 1Gi), in agreement with
previous studies with LPS-stimulated macrophages (32). Further-
more, infection of WT and Ifnar12/2 macrophages revealed that
type I IFN signaling was required for IL-27 production upon M.
tuberculosis infection (Fig. 1Gii).
We then investigated whether IL-27 was required for IL-10
production in M. tuberculosis–infected macrophages, and also for
promotion of IL-10 production by type I IFN. This was done by
infecting WT and Tccr2/2 macrophages (that lack the IL-27R
a-chain and hence a functional IL-27 receptor) (50) with M. tu-
berculosis in the presence or absence of IFN-b (Fig. 1H). As ex-
pected,M. tuberculosis–infected WT macrophages produced IL-10
and the levels of IL-10 were increased by addition of IFN-b
(Fig. 1H). Tccr2/2 macrophages also produced IL-10 in response
to M. tuberculosis infection, and levels were also increased upon
addition of IFN-b (Fig. 1H). Levels of TNF-a and other proin-
flammatory cytokines were not reproducibly different between
WTand Tccr2/2macrophages infected withM. tuberculosis (Fig. 1I
and data not shown). Resting BMDMs expressed only low levels of
the transcripts for both IL-27R subunits compared with naive
T cells (Supplemental Fig. 1A). LPS- or CpG-treated BMDMs
(Supplemental Fig. 1B), BM-derived dendritic cells, and BM
monocytes (data not shown) did not produce different levels of IL-
10 following treatment with rIL-27. These data suggest that IL-27R
signaling is not required for IL-10 production by M. tuberculosis–
infected macrophages or for IFN-b–mediated enhancement of IL-
10 production by M. tuberculosis–infected macrophages.
It has previously been suggested that IL-27 induces IL-10
downstream of type I IFN in BMDMs in a STAT-1– and STAT-3–
dependent manner (32). To investigate whether WT BMDMs
activated STAT-1 and STAT-3 following IL-27 treatment and to con-
firm that Tccr2/2 cells did not transduce any signal from IL-27,
we treated BMDMs from WT and Tccr2/2 mice with rIL-27 for
20 min and then probed by Western blot for phosphorylation of
STAT-1 and STAT-3 (Fig. 1J). Neither STAT-1 nor STAT-3 was phos-
phorylated in response to IL-27 in both WT and Tccr2/2 macro-
phages (Fig. 1J). BMDMs of both genotypes were capable of phos-
phorylating STAT-1 and STAT-3, because p–STAT-1 and p–STAT-3
were detected in both in response to IFN-g or IL-10 addition, which
led to phosphorylation of STAT-1 and STAT-3, respectively (Fig. 1J).
To control for the possibility that WT BMDMs might upregulate
IL-27R following TLR stimulation and thereby activate STAT-1
and/or STAT-3 in response to IL-27 treatment in the presence of
TLR activation, we stimulated WT and Tccr2/2 macrophages with
the TLR2 agonist Pam3CSK4 for 0, 3, or 6 h, treated them with
IL-27 for 20 min, and then assayed for phosphorylation of STAT-1
and STAT-3 using Western blot (Fig. 1K). We specifically chose
Pam3CSK4 as a stimulus, as it does not activate STAT-1 and only
activates low levels of STAT-3 (data not shown) and hence would
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FIGURE 1. Type I IFN regulates IL-10 production in M. tuberculosis–infected macrophages independently of IL-27 signaling. (A) WT macrophages
were infected with M. tuberculosis in the presence of increasing concentrations of IFN-b, added at the time of infection, and levels of IL-10 in culture
supernatant were determined by ELISA at 24 h postinfection. (B) WT macrophages were infected with M. tuberculosis in the presence or absence of 2 ng/ml
IFN-b, added at the time of infection, and levels of Il10mRNAwere determined by quantitative RT-PCR (qRT-PCR) at the time points indicated after infection.
(C) WT and Ifnar12/2 macrophages were infected with M. tuberculosis and levels of IL-10 in culture supernatant were determined by ELISA at 24 h post-
infection. (D) WTand Ifnar12/2macrophages were infected withM. tuberculosis and levels of Il10mRNA determined by qRT-PCR at the time points indicated
after infection. (E) WT myeloid cells taken ex vivo from lungs (i) and BM (ii) were infected withM. tuberculosis in the presence or absence of 2 ng/ml IFN-b,
added at the time of infection, and levels of IL-10 in culture supernatant were determined by Luminex bead array at 24 h postinfection. (F) WT, Ifnar12/2, and
WT treated with IFN-b macrophages were infected with M. tuberculosis, and at 1 h postinfection ActD was added. mRNAwas then taken at the time points
indicated and Il10 mRNA levels were determined by qRT-PCR. (G) WT macrophages treated (or not) with 2 ng/ml IFN-b at the time of infection (i) and WT
and Ifnar12/2 macrophages (ii) were infected withM. tuberculosis, and levels of IL-27 in culture supernatant were determined by ELISA at 24 h postinfection.
(H and I) WT and Tccr2/2 (IL-27Ra2/2) macrophages were infected with M. tuberculosis in the presence or absence of 2 ng/ml IFN-b, added at the time of
infection, and levels of IL-10 (H) or TNF-a (I) in culture supernatant were determined by ELISA at 24 h postinfection. (J) WT and Tccr2/2 (IL-27Ra2/2)
macrophages were treated for 20 min with rIL-27 (50 ng/ml), rIFN-g (10 ng/ml), or rIL-10 (10 ng/ml) and whole-cell extracts were then analyzed by im-
munoblotting with the indicated Abs. (K) WT and Tccr2/2 (IL-27Ra2/2) macrophages were stimulated for 0, 3, or 6 h with Pam3CSK4 (200 ng/ml) and then
treated (or not) for 20 min with rIL-27 (50 ng/ml). WT macrophages treated with IFN-g (10 ng/ml) or IL-10 (10 ng/ml) were included as positive controls for
STAT-1 and STAT-3 phosphorylation, respectively. Whole-cell extracts were then analyzed by immunoblotting with the indicated Abs. (L) WT and Tccr2/2
splenocytes were treated for the indicated times with rIL-27 (50 ng/ml) or rIFN-g (10 ng/ml). Whole-cell extracts were then (Figure legend continues)
4 TYPE I IFN INDUCES IL-10 and BLOCKS IFN-g IN INFECTED BMDMs
minimally confound any effects of IL-27 that other stimuli that
activate these STATs would. STAT-3 was phosphorylated in both
WT and Tccr2/2 macrophages 3 and 6 h after stimulation with
Pam3CSK4, but this was not enhanced further by treatment with
IL-27 or reduced in Tccr2/2 cells (Fig. 1K). STAT-1 phosphory-
lation was not induced under these conditions but could be in-
duced by addition of IFN-g (Fig. 1K).
However, rIL-27 was capable of activating signaling in other
WT cells, because STAT-1 was phosphorylated in whole spleno-
cytes treated with IL-27 for 10 or 30 min but not in Tccr2/2
splenocytes, demonstrating both the activity of the recombinant
cytokine and the specificity of the knockout (Fig. 1L). These
data confirm that the IL-27R in the Tccr2/2 mice used is non-
functional.
Collectively, our data demonstrate that although IL-27 is in-
duced by type I IFN, IL-27 is not required for type I IFN–mediated
IL-10 upregulation by M. tuberculosis–infected macrophages.
Exogenous IFN-b inhibits IL-12, TNF, and IL-1b production in
M. tuberculosis–infected macrophages despite type I IFN
signaling being required for optimal IL-12p40 and TNF-a
production
We next wanted to examine how type I IFN might affect produc-
tion by macrophages of proinflammatory cytokines important in
host protection against M. tuberculosis. During in vivo M. tuber-
culosis infection a number of diverse cell types may produce type
I IFN to influence macrophage function. We therefore initially
sought to assess the effects of exogenous sources of type I IFN on
proinflammatory cytokine production by M. tuberculosis–infected
macrophages by infecting WT macrophages with M. tuberculosis
and concomitantly adding rIFN-b at varying doses (Fig. 2A,
2B). Addition of IFN-b to M. tuberculosis–infected macrophages
inhibited both IL-12p40 and TNF-a production (Fig. 2A).
IL12p40 production appeared to be more sensitive than TNF-a
to IFN-b treatment, being inhibited greatly at doses as low as
0.02 ng/ml, whereas TNF-a production was only inhibited at
doses of 0.2 ng/ml or higher (Fig. 2A). IL-12p70 protein was not
detected in any group (limit of detection [LOD], 20 pg/ml) (Fig. 2A).
Levels of gene transcription for these cytokines were also assessed
following addition of 2 ng/ml IFN-b to M. tuberculosis–infected
macrophages. Il12b mRNA was not significantly affected at 1 h
postinfection by addition of IFN-b but was greatly decreased
in IFN-b–treated, M. tuberculosis–infected macrophages at
6 h compared with M. tuberculosis–infected alone macrophages
(Fig. 2A). Similarly, Tnfa mRNA levels were lower at 6 h post-
infection in IFN-b–treated macrophages but not at 1 h (Fig. 2A).
Conversely, IFN-b treatment reduced Il12a mRNA in infected
macrophages compared withM. tuberculosis–infected alone macro-
phages at 1 h but not at 6 h postinfection (Fig. 2A). Levels of
IL-1b production were also assessed in M. tuberculosis–in-
fected macrophages treated with IFN-b (Fig. 2B). Similar to the
findings for IL-12p40 and TNF-a, IL-1b production was inhibited
by IFN-b addition, with IL-1b protein levels being reduced at
doses of 0.02 ng/ml or higher (Fig. 2B). Il1b mRNA levels were
also reduced following IFN-b treatment of M. tuberculosis–
infected macrophages, being reduced at 1 and 6 h postinfection
compared with M. tuberculosis–infected alone macrophages
(Fig. 2B).
We next examined what effects autocrine type I IFN signaling
had on proinflammatory cytokine production upon infection of
WT and Ifnar12/2 macrophages with M. tuberculosis. Unex-
pectedly, given the previous results with addition of IFN-b, the
amount of IL-12p40 secreted was reduced in M. tuberculosis–
infected Ifnar12/2 macrophages compared with WT cells, as were
the levels of Il12b mRNA at 1 and 6 h postinfection (Fig. 2C).
IL-12p70 was not detectable from either WT or Ifnar12/2 mac-
rophages infected with M. tuberculosis (LOD, 20 pg/ml). How-
ever, Il12a mRNA levels were reduced in Ifnar12/2 macrophages
compared with WT at 6 h postinfection (Fig. 2C). Additionally,
TNF-a protein production and Tnfa mRNA levels were also re-
duced in Ifnar12/2 compared with WT macrophages following
M. tuberculosis infection (Fig. 2C). In contrast to these cytokines,
the secretion of IL-1b was increased in Ifnar12/2 macrophages in
response to M. tuberculosis infection as compared with WT cells,
despite Il1b mRNA levels also being reduced at 6 h (Fig. 2D).
Collectively, these results suggest that although high levels of
IFN-b inhibit the ability of macrophages to make proinflammatory
cytokines, paradoxically, autocrine type I IFN signaling is re-
quired in macrophages for optimal production of IL-12p40 and
TNF-a following M. tuberculosis infection but still inhibits
macrophage production of IL-1b.
Timing of IFN signaling determines effects on macrophage
cytokine production upon M. tuberculosis infection
To investigate whether timing of type I IFN signaling relative to
M. tuberculosis infection might explain the differences in cytokine
production observed between addition of recombinant type I IFN
and autocrine type I IFN signaling, we pretreated macrophages for
varying times prior to M. tuberculosis infection. Pretreatment of
macrophages with IFN-b for 8 or 12 h prior to M. tuberculosis
infection enhanced IL-12p40, and to a lesser extent TNF-a pro-
duction, indicating that timing of IFN signaling relative to sig-
naling through pattern recognition receptors is important in
determining the effects of type I IFN in regulating the secretion
of these proinflammatory cytokines (Fig. 3). IL-12p70 protein
was not detected in any group (LOD, 20 pg/ml). IL-10 levels
were enhanced by pre-addition of IFN-b at all time points tested
but had the greatest effect when added at or shortly before
M. tuberculosis infection (Fig. 3). IL-1b production by macrophages
upon M. tuberculosis infection was inhibited by pre-addition of
type I IFN, at most pretreatment time points investigated, although
this did not significantly affect IL-1b levels at 12 h of pretreatment
(Fig. 3). Again, the greatest effect was seen when IFN-b was
added close to the time of infection.
Exogenous IFN-b inhibits macrophage responsiveness to
concomitant IFN-g addition
IFN-g is crucial to the host response against M. tuberculosis in-
fection (10, 14) and is known to induce or enhance production of
important host-protective cytokines such as IL-12 and TNF-a by
macrophages and other myeloid cells while inhibiting IL-10 pro-
duction (5, 9, 13, 14, 51–53). Because exogenous type I IFN and
exogenous IFN-g appear to have opposing effects on macrophages,
we investigated which IFN type would have a dominant effect in
influencing macrophage cytokine production following M. tuber-
culosis infection. To test this we infected WT macrophages with
analyzed by immunoblotting with the indicated Abs. Graphs show means 6 SEM of triplicate samples, except for (E), which shows duplicates. For ELISA
and Luminex bead array results, uninfected control samples were below the detection limit (20 and 5 pg/ml, respectively) for the cytokines measured (data
not shown). Significance was determined using an unpaired t test (A, C, E, and G), a one-way ANOVAwith a Bonferroni post hoc test (H and I), or a two-way
ANOVA, with significance relative to WT (F). Data are representative of at least two independent experiments. *p , 0.05, **p , 0.01, ***p , 0.001.
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M. tuberculosis, also adding IFN-g and IFN-b at the time of in-
fection (Fig. 4).M. tuberculosis–infected macrophages treated singly
with IFN-g or IFN-b or left untreated were included as controls.
As expected, IL-10 production was inhibited in M. tuberculosis–
infected macrophages treated with IFN-g alone and enhanced in
M. tuberculosis–infected macrophages treated with IFN-b alone
(Fig. 4A). When both IFN-g and IFN-b were added to macrophages
infected with M. tuberculosis, IL-10 production was enhanced to
a level at least equal to that seen with IFN-b alone, suggesting
that IFN-b was overriding IFN-g–mediated inhibition of IL-10
(Fig. 4A). Il10 mRNA levels at 6 h postinfection were similarly
affected by IFN treatment (Supplemental Fig. 2). A similar trend
was seen with IL-12p40 production by M. tuberculosis–infected
macrophages; that is, whereas IFN-g alone greatly promoted IL-
12p40 production, IFN-b alone and IFN-b together with IFN-g
resulted in markedly reduced levels of IL-12p40 (Fig. 4A). Similar
results were found at the transcriptional level with Il12a and Il12b
mRNA (Supplemental Fig. 2). TNF-a production by macrophages
infected with M. tuberculosis was similarly affected, with IFN-g
alone promoting TNF-a, whereas IFN-b alone and IFN-b/IFN-g
together resulted in inhibition of TNF-a production (Fig. 4A). Tnfa
mRNA, however, did not follow this trend, being downregulated by
both IFN-g and IFN-b (Supplemental Fig. 2). Effects on IL-27 and
IL-1b were the exception to the trend of IFN-b overriding IFN-g.
FIGURE 2. Opposing effects of exogenous IFN-b treatment and auto-
crine type I IFN signaling on IL-12 and TNF-a production in M. tuber-
culosis–infected macrophages. (A) WT macrophages were infected with
M. tuberculosis in the presence of increasing concentrations of IFN-b (for
protein) or 2 ng/ml IFN-b (for mRNA), added at the time of infection, and
levels of IL-12p40, IL-12p70, and TNF-a protein in supernatant and Il12b,
Il12a, and Tnfa mRNA from cells were determined by ELISA at 24 h
postinfection and qRT-PCR at indicated times after infection. (B) IL-1b
protein and Il1b mRNA from macrophages in (A) were measured by
ELISA at 24 h postinfection and qRT-PCR at indicated times after infec-
tion. (C) WT and Ifnar12/2 macrophages were infected with M. tubercu-
losis and IL-12p40, IL-12p70, and TNF-a protein in supernatant and Il12b,
Il12a, and Tnfa mRNA from cells were determined by ELISA at 24 h
postinfection and qRT-PCR at indicated times after infection. (D) IL-1b
protein and Il1b mRNA from macrophages in (C) were measured by
ELISA at 24 h postinfection and qRT-PCR at indicated times after infec-
tion. Graphs show means 6 SEM of triplicate samples. For ELISA results,
uninfected control samples were below the detection limit (20 pg/ml) for
the cytokines measured (data not shown). Significance was determined
using an unpaired t test. Data are representative of at least three inde-
pendent experiments. *p , 0.05, **p , 0.01, ***p , 0.001.
FIGURE 3. IFN-b pretreatment of M. tuberculosis–infected macro-
phages enhances IL-12 and TNF-a production. WT macrophages were
infected with M. tuberculosis alone or in the presence of IFN-b (2 ng/ml),
added at the indicated times prior to infection. Cytokine levels in culture
supernatants were determined by ELISA at 24 h postinfection. Uninfected
control samples were below the detection limit (20 pg/ml) for the cytokines
measured (data not shown). Graphs show means 6 SEM of triplicate
samples. Data are representative of two independent experiments. Signif-
icance was determined using a two-way ANOVA with a Bonferroni post
hoc test. *p , 0.05, **p , 0.01, ***p , 0.001.
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IL-27 production was upregulated by both IFN-g and IFN-b and
further upregulated when both were added concomitantly (Fig.
4A). IFN-g alone and IFN-b alone treatment both inhibited IL-1b
production from M. tuberculosis–infected macrophages, although
IFN-g was slightly more potent than IFN-b (Fig. 4A). When both
IFN-b and IFN-g were added to M. tuberculosis–infected macro-
phages, IL-1b levels were reduced to a level below the single cy-
tokine treatment groups (Fig. 4A). mRNA levels were similarly
affected (Supplemental Fig. 2). In addition to adding both IFN to
macrophages at the time of infection, we also repeated the experi-
ment with 2 h of IFN-b pretreatment, prior to infection and IFN-g
addition, or 2 h of IFN-g pretreatment, followed by infection and
IFN-b addition, and we found the same results in both cases as
adding both IFN at the time of infection that type I IFN effects are
dominant (data not shown). Type I IFN has been shown to inhibit
IFN-g responsiveness during L. monocytogenes infection through
inhibiting transcription of the gene encoding IFN-g receptor sub-
unit 1 (43, 54). We therefore examined mRNA levels of Ifngr1
during M. tuberculosis infection of macrophages. Downregulation
of Ifngr1 mRNA levels upon M. tuberculosis infection could be
observed, but this was only partially dependent on type I IFN sig-
naling (data not shown), illustrating the complexity of this system.
Finally, to confirm that similar responses to IFN-b and IFN-g
were seen in ex vivo–derived cells, primary myeloid cells were
sorted from the lungs and BM of WT mice, M. tuberculosis
infected, and IFN treated as for experiments with BMDMs (Fig. 4B,
4C). Although overall levels of IL-12p40 were low in supernatant
from M. tuberculosis–infected lung and BM myeloid cells, these
cells responded similarly to BMDMs upon IFN treatment, with
IFN-g enhancing IL12p40 levels and IFN-b treatment inhibiting
IFN-g–mediated IL-12p40 production (Fig. 4B, 4C). IL-12p70 was
not detected under any condition (Fig. 4). For TNF-a production,
lung myeloid cells also showed a similar pattern of response to
M. tuberculosis infection and IFN treatment as for IL-12p40, with the
upregulation induced by IFN-g being repressed by IFN-b treatment
(Fig. 4B). In BM myeloid cells levels of TNF-a were not affected
by IFN-g compared with M. tuberculosis infection alone, whereas
IFN-b treatment resulted in a modest, but significant reduction
compared with M. tuberculosis infection alone and M. tuberculosis
infection plus IFN-g (Fig. 4C). Similar to findings in BMDMs, IL-
1b production by M. tuberculosis–infected lung and BM myeloid
cells was inhibited by both IFN-g and IFN-b (Fig. 4B, 4C).
Collectively, these results suggest that exogenous type I IFN
powerfully overcomes the macrophage response to IFN-g during
FIGURE 4. Exogenous IFN-b inhibits M. tuber-
culosis–infected macrophage responsiveness to
concomitant IFN-g addition. (A) WT macrophages
were infected with M. tuberculosis alone or with M.
tuberculosis and IFN-b (2 ng/ml), M. tuberculosis
and IFN-g (5 ng/ml), or M. tuberculosis and both
IFN-b (2 ng/ml) and IFN-g (5 ng/ml) together,
added at the time of infection. Cytokine levels in
culture supernatants were determined at 24 h post-
infection. Uninfected control samples were below
the detection limit (20 pg/ml) for the cytokines
measured (data not shown). Graphs show means 6
SEM. Significance was determined using a one-way
ANOVA with a Bonferroni post hoc test. Data are
representative of three independent experiments. (B)
Myeloid cells (Lin2Ly6c+Ly6G2) were sorted from
the lungs of WT mice and infected with M. tuber-
culosis and treated with IFN as in (A). Cytokine
levels in culture supernatant were determined at 24 h
postinfection using a Luminex bead array. Unin-
fected control samples were below the detection
limit (5 pg/ml) for the cytokines measured (data not
shown). Graphs show means 6 SEM. Data are
representative of two independent experiments. (C)
Myeloid cells (Lin2Ly6c+Ly6G2) were sorted from
the BM ofWT mice and infected withM. tuberculosis
and treated with IFN as in (A) and (B). Cytokine
levels in culture supernatant were determined at 24 h
postinfection using a Luminex bead array. Unin-
fected control samples were below the detection
limit for the cytokines measured (data not shown).
Graphs show means6 SEM. Data are representative
of three independent experiments. *p , 0.05, **p ,
0.01, ***p , 0.001.
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M. tuberculosis infection. However, this effect is not universal, as
seen with IL-1b production, where both cytokines are inhibitory.
Exogenous IFN-b inhibits IL-12, TNF-a, and IL-1b production
in M. tuberculosis–infected macrophages through
IL-10–dependent and –independent mechanisms
IL-10 is a prominent inhibitor of myeloid cell functions (55).
Given our previous results, we hypothesized that type I IFN was me-
diating its suppressive effects on proinflammatory cytokine produc-
tion by M. tuberculosis–infected macrophages through induction of
IL-10. To test this we infected IL-10–deficient macrophages with
M. tuberculosis with and without addition of IFN-b (Fig. 5A). Il102/2
macrophages produced greatly increased levels of IL-12p40 com-
pared with WT cells upon M. tuberculosis infection (Fig. 5A). Addi-
tion of IFN-b to Il102/2 macrophages reduced IL-12p40 levels, but
not to the same extent as IFN-b added to WT macrophages infected
with M. tuberculosis (∼25% reduction in Il102/2 cells versus ∼70%
in WT cells) (Fig. 5A). These results suggested that the inhibitory
effect of IFN-b on IL-12p40 production is largely dependent on IL-
10. IL-12p70 was not detectable in any group. TNF-a production
was similarly increased in Il102/2 M. tuberculosis–infected macro-
phages compared with WT cells (Fig. 5A). IFN-b treatment did not
result in reduced TNF-a in Il102/2 macrophages, indicating that the
inhibitory effects of IFN-b on TNF-a production are totally depen-
dent on IL-10 (Fig. 5A). Although IL-10 reduced the ability of
macrophages to produce IL-27 following M. tuberculosis infection,
it did not greatly affect the ability of IFN-b treatment to enhance
IL-27 production (Fig. 5A). IL-1b production was only increased
by 30% in M. tuberculosis–infected Il102/2 macrophages compared
with WT controls. IFN-b treatment was still able to significantly
inhibit IL-1b production by IL-10–deficient macrophages infected
with M. tuberculosis (Fig. 5A). This suggested that type I IFN
had a dominant inhibitory effect on IL-1b that was minimally de-
pendent on IL-10 during M. tuberculosis infection of macrophages.
Type I IFN signaling impairs IFN-g effects on
M. tuberculosis–infected macrophage cytokine production
via IL-10–dependent and –independent mechanisms
As described above, IFN-g is crucial to the host response against
M. tuberculosis infection (10, 14) and is known to induce or en-
hance production of important host-protective cytokines such as
IL-12 (5, 9, 13, 14, 51–53). We noted that even in the absence of
type I IFN or IL-10 signaling macrophages could not be induced
to consistently make significant amounts of IL-12p70, the bio-
logically active form of IL-12, upon M. tuberculosis infection.
This indicated that removal of inhibitory signals alone might not
be sufficient for induction of robust levels of this cytokine and that
IFN-g may be required.
FIGURE 5. Exogenous IFN-b and endogenous type I
IFN signaling affect proinflammatory cytokine production
and responsiveness to IFN-g in M. tuberculosis–infected
macrophages through IL-10–dependent and –independent
mechanisms. (A) WT and Il102/2 macrophages were infec-
ted with M. tuberculosis or with M. tuberculosis and IFN-b
(2 ng/ml), added at the time of infection. Levels of the
indicated cytokines in culture supernatant were determined
at 24 h postinfection by ELISA. Graphs show means 6
SEM of triplicate samples. Significance was determined
using a one-way ANOVA with a Bonferroni post hoc test.
(B) WT and Ifnar12/2 macrophages were infected with
M. tuberculosis, treated with anti–IL-10R or isotype control
Abs and with IFN-g (5 ng/ml) or not, added at the time of
infection. Levels of the indicated cytokines in culture su-
pernatant were determined at 24 h postinfection by ELISA.
Uninfected control samples were below the detection limit
(20 pg/ml) for the cytokines measured (data not shown).
Graphs show means 6 SEM of triplicate samples. Data
are representative of three independent experiments. *p ,
0.05, **p , 0.01, ***p , 0.001.
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To confirm that IFN-g was required for IL-12p70 production in
M. tuberculosis–infected macrophages and to test whether type I
IFN together with IL-10 might exert negative regulatory effects on
IFN-g action, we infected WT or Ifnar12/2 macrophages with
M. tuberculosis in the presence or absence of rIFN-g and anti–
IL-10R or anti–IL-10 Abs (Fig. 5B and data not shown). IL-12p40
production could be enhanced in M. tuberculosis–infected WT
macrophages either treated with IFN-g or anti–IL-10R and was
further enhanced in M. tuberculosis–infected Ifnar12/2 macro-
phages treated with IFN-g or IFN-g and anti–IL-10R (Fig. 5B).
Addition of IFN-g, a known inducer of IL-12p70 in concert with
TLR signals (51, 53, 56), induced little to no IL-12p70 in
M. tuberculosis–infected WT macrophages (Fig. 5B). However, in
the absence of type I IFN signaling or upon Ab blockade of the
IL-10R, IFN-g was able to induce robustly detectable levels of
IL-12p70 production (Fig. 5B). TNF-a production by M. tuber-
culosis–infected macrophages was also enhanced upon IFN-g
treatment, and this was not further increased by abrogation of the
type I IFN receptor but was increased upon anti–IL-10R blockade
(Fig. 5B). As expected, IL-27 levels were greatly impaired in
Ifnar12/2 BMDMs compared with WT, and although anti–IL-10R
blockade and IFN-g treatment increased IL-27 in both WT and
Ifnar12/2, levels in the type I IFN receptor–deficient BMDMs
could not be rescued to those of the WT controls (Fig. 5B).
IL-1b production by both WT and Ifnar12/2 M. tuberculosis–
infected macrophages was greatly inhibited by IFN-g addition
(Fig. 5B). The relative level of inhibition was similar between WT
and Ifnar12/2 macrophages, although there was a trend to greater
inhibition in the Ifnar12/2 macrophages (Fig. 5B).
Altogether, these results are in agreement with previous studies
reporting that IFN-g is an important inducer and/or enhancer of
IL-12 and TNF-a production. However, we now show that during
M. tuberculosis infection of macrophages the ability of IFN-g to
positively regulate production of these cytokines is significantly
impaired by both autocrine type I IFN and IL-10. Production of
bioactive IL-12p70, in particular, is strongly suppressed by these
two negative regulatory factors.
Type I IFN regulation of IL-1b production is dependent on
inducible NO synthase and IL-10
In contrast to type I IFN effects on TNF-a, we found that inhibition
of IL-1b (and IL-12) production by IFN-b was only partially
dependent on IL-10. Additionally, we observed co-operative in-
hibition of IL-1b by IFN-g and IFN-b, in contrast to their usually
cross-regulatory effects on each other’s action on cytokine pro-
duction. IFN-g has recently been described to negatively regulate
IL-1b production during M. tuberculosis infection in an inducible
NO synthase (iNOS, gene name Nos2)–dependent manner (57).
Because type I IFN can also induce iNOS, we hypothesized that
IFN-b was also inhibiting IL-1b production through upregulation
of iNOS. To test this we infected WT and Nos22/2 BMDMs with
M. tuberculosis and concomitantly added IFN-g or IFN-b (Fig. 6).
We also included groups treated with anti–IL-10R blocking Abs to
compare IL-10 effects versus iNOS effects (Fig. 6).
In macrophages infected with M. tuberculosis alone, abrogation
of Nos2 had only minor effects on IL-1b production (Fig. 6).
However, in M. tuberculosis–infected Nos22/2 BMDMs treated
with anti–IL-10R Abs levels of IL-1b were elevated over levels in
infected WT, anti–IL-10R-treated BMDMs, suggestive of IL-10
regulation of iNOS and/or its function (Fig. 6). When M. tuber-
culosis–infected WT macrophages were treated with IFN-g, IL-1b
production was almost entirely abrogated and this abrogation was
completely relieved in infected Nos22/2 BMDMs treated with
IFN-g (Fig. 6). This suggests that iNOS mediates suppression of
IL-1b production by IFN-g, in agreement with the findings of
Mishra et al. (57). IL-10R blockade had little effect on macro-
phages treated with IFN-g, likely due to IFN-g suppressing IL-10
production (Fig. 6; see Fig. 4). As expected, IL-1b production by
M. tuberculosis–infected macrophages was also suppressed by
treatment with IFN-b (Fig. 6). This was partially relieved by the
abrogation of iNOS, but not to the same extent as seen in IFN-g–
treated groups (Fig. 6). Ab blockade of IL-10R in IFN-b–treated,
M. tuberculosis–infected macrophages lacking Nos2 did restore
IL-1b levels to those of WT infected, untreated macrophages,
FIGURE 6. Type I IFN regulation of IL-1b production is dependent on
iNOS and IL-10. WT and Nos22/2 macrophages were infected with
M. tuberculosis, treated with anti–IL-10R or isotype control Abs and with
either IFN-g (5 ng/ml) or IFN-b (2 ng/ml) or media, added at the time of
infection. Levels of the indicated cytokines in culture supernatant were
determined at 24 h postinfection by ELISA. Uninfected control samples
were below the detection limit (20 pg/ml) for the cytokines measured (data
not shown). Graphs show means 6 SEM of triplicate samples. Data are
representative of at least three independent experiments.
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suggesting that IFN-b inhibits IL-1b production through the dual
mechanisms of IL-10 and iNOS (Fig. 6).
Interestingly, we also noted that although iNOS did not greatly
affect production of the other cytokines measured in M. tubercu-
losis–infected alone macrophages or M. tuberculosis–infected and
IFN-b–treated macrophages, in macrophages infected with M. tu-
berculosis and treated with IFN-g, levels of IL-12 and IL-27
were elevated in the absence of Nos2 (Fig. 6). This suggests that
iNOS also acts as a feedback negative regulator of IFN-g function.
Type I IFN signaling inhibits macrophage restriction of
M. tuberculosis growth and killing in response to IFN-g
In addition to induction of crucial host-protective cytokines, IFN-g
is known to be important in activating macrophages to restrict
intracellular bacterial growth, including that of M. tuberculosis (5,
6, 11, 12, 58, 59). Indeed, IFN-g has been shown to be the crucial
cytokine for induction of the reactive nitrogen and oxygen species
that are necessary for antimicrobial activity in murine macro-
phages (60). In view of our previous results showing that IFN-b
interferes with the IFN-g–mediated regulation of several cyto-
kines, we next investigated whether type I IFN signaling could
also affect IFN-g–mediated restriction of M. tuberculosis in
infected macrophages. To study this, WT and Ifnar12/2 macro-
phages were infected with M. tuberculosis in the presence or ab-
sence of IFN-g, and at 96 h postinfection bacterial loads were
assessed (Fig. 7). We employed two methods of infection for these
experiments: either leaving bacteria in the well for the full 96 h
postinfection (Fig. 7, top) or washing out after 4 h of infection
(Fig. 7, bottom), with matching results being observed between
the two. Additionally, we controlled for differences in bacterial
uptake between WT and Ifnar12/2 macrophages by enumerating
CFUs at 4 h postinfection, and we found no difference between
the two cell types (data not shown). Bacterial loads were not
significantly different between WT and Ifnar12/2 macrophages
infected withM. tuberculosis alone with no wash but were slightly
increased in Ifnar12/2 cells versus WT when the M. tuberculosis
inoculum was washed out (Fig. 7). IFN-g treatment induced a reduc-
tion in bacterial load in WT macrophages of ∼2-fold compared
with M. tuberculosis infection alone, but treatment of Ifnar12/2
macrophages with IFN-g led to a reduction in bacterial load of
.5-fold compared with Ifnar12/2 macrophages infected with
M. tuberculosis alone (Fig. 7). Addition of IFN-b toM. tuberculosis–
infected WT macrophages did not alter bacterial loads compared
with M. tuberculosis infection alone (data not shown). Treatment
of M. tuberculosis–infected macrophages with IFN-g and IFN-b
together did not alter bacterial loads compared with M. tubercu-
losis–infected macrophages treated with IFN-g alone (data not
shown). These results suggest that endogenous levels of type I IFN
induced by M. tuberculosis infection can inhibit the ability of
IFN-g to restrict bacterial levels in M. tuberculosis–infected
macrophages, in addition to inhibiting IFN-g effects on macro-
phage cytokine production during M. tuberculosis infection.
Discussion
There is growing evidence in both mice and humans that type I
IFNs are detrimental to host resistance during TB (15, 16, 18–25,
29). However, the mechanisms by which type I IFN negatively
impacts the host response to M. tuberculosis are not well under-
stood. Several recent studies have highlighted the importance of
type I IFN in the myeloid cell response to M. tuberculosis (16, 20,
21, 25). In this study, we show that type I IFN signaling is required
for macrophage induction of the immunosuppressive cytokine
IL-10 during M. tuberculosis infection. Type I IFN is also re-
sponsible for suppressing production of several proinflammatory
cytokines by macrophages, particularly IL-12, TNF-a, and IL-1b,
which are considered crucial to host protection against M. tuber-
culosis (7, 8, 20, 61–64). IL-10 is an important mediator of the
suppressive effect on IL-12 and TNF-a production. IFN-g is a key
cytokine for activation of myeloid cells to both produce increased
levels of protective cytokines, particularly IL-12, and to restrict
intracellular bacterial growth (5, 6, 9, 11–13, 58, 65). Importantly,
we now show that type I IFN dramatically suppresses the mac-
rophage response to IFN-g for induction of IL-12p40 and
IL-12p70, as well as for M. tuberculosis growth restriction and
killing.
We first investigated the effect of type I IFN on IL-10 produc-
tion by macrophages infected with M. tuberculosis and found both
a requirement for type I IFN signaling in induction of IL-10 and
an increase in IL-10 production following addition of exogenous
IFN-b to M. tuberculosis–infected macrophages, in agreement
with several other studies in different systems, such as LPS
stimulation (30–32). Analysis of Il10 mRNA levels suggested that
type I IFN mediated its effects on IL-10 production through reg-
ulating initial transcription of the Il10 gene but also through sta-
bilization of Il10 transcripts. IL-27 has previously been reported
as a mediator of IL-10 induction downstream of type I IFN fol-
lowing LPS stimulation of BMDMs (32). This induction of IL-10
by IL-27 was reported to be dependent on STAT-1 and STAT-3
FIGURE 7. Type I IFN signaling inhibits macrophage restriction of
M. tuberculosis growth and killing in response to IFN-g. WT and Ifnar12/2
macrophages were infected withM. tuberculosis in the presence or absence
of IFN-g (5 ng/ml), added at the time of infection. At 4 h postinfection
media containingM. tuberculosis was removed, cells were washed in PBS,
and fresh media (with no M. tuberculosis) were replaced (bottom panel) or
not (top panel). At 96 h postinfection cells were washed in PBS, lysed in
0.2% saponin, and bacterial loads were enumerated via serial dilution and
plating. Line and bars show means 6 SEM. Significance was determined
using an unpaired t test. Data are representative of at least two independent
experiments for each of the two systems (i.e., wash or no wash). **p ,
0.01, ***p , 0.001.
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activation (32). We found that type I IFN was required for in-
duction of IL-27 in M. tuberculosis–infected macrophages and
that addition of IFN-b enhanced IL-27 production, in agreement
with this study and others (32, 66). However, we found no re-
quirement for IL-27 signaling in IL-10 induction or enhancement
of IL-10 production by IFN-b. IL-10 production by BM-derived
dendritic cells and BM monocytes was also unaffected by IL-27.
Furthermore, our BMDMs did not activate STAT-1 and STAT-3
following IL-27 treatment, in keeping with another study (48)
that also did not detect STAT-1 and STAT-3 phosphorylation in
BMDMs following IL-27 treatment. In this study the authors
could not detect induction of STAT-1–dependent genes in
BMDMs following IL-27 treatment and reported low levels of
IL-27R expression, suggesting that these cells were “minimally
responsive” to IL-27 (48). We also found low relative levels of IL-
27R expression in our BMDMs, in accordance with this study (48)
and others who found low relative levels of IL-27R expression on
F4/80+ splenic macrophages (67) and plastic adherent splenic
macrophages (50), whereas we show that T cells do express the
IL-27R, as others report (50, 67). Although this lack of STAT-1
and STAT-3 activation is in contrast to Iyer et al. (32), the reasons
for the difference between our findings and those of Iyer et al. are
presently unclear, but may be due to laboratory differences in
generation and culture conditions of BMDMs. Note that our
findings do not exclude IL-27 responsiveness by other types of
macrophage or myeloid cell that may also respond in a manner not
assessed in this study (68, 69).
We also investigated the effects of type I IFN on proin-
flammatory cytokine production. Addition of IFN-b to M. tuber-
culosis–infected macrophages potently suppressed IL-12p40
production, in agreement with a number of studies in viral and
some bacterial models showing suppression of IL-12 by type I
IFN (24, 70–73). TNF-a and IL-1b production were also sup-
pressed by type I IFN addition. Interestingly, and in contrast to
these findings, autocrine type I IFN was also partially required for
optimal IL-12p40 and TNF-a production by macrophages fol-
lowing M. tuberculosis infection, in agreement with a previous
study where type I IFN signaling was required for IL-12 pro-
duction following TLR stimulation (74). The discrepancy between
our results with addition of IFN-b versus deficiency in type I IFN
signaling appears to be due to the timing of type I IFN signaling
relative to signaling through pattern recognition receptors, because
12 h of pretreatment with IFN-b resulted in increased levels of IL-
12 and TNF-a upon M. tuberculosis infection, whereas IFN-b
treatment proximal to M. tuberculosis infection consistently
resulted in suppression of IL-12p40 and TNF-a production. This
may indicate that distinct mechanistic programs of action of type I
IFN exist, dependent on proximity to other stimuli (such as in-
fection).
In contrast to IL-12p40 and TNF-a, type I IFN signaling
inhibited macrophage production of IL-1b protein following
M. tuberculosis infection under all conditions tested. This is in clear
agreement with recent studies in both mouse models (20) and
human cells (21) and illustrates an important mechanism of type I
IFN negative regulation of the host response, because IL-1 is
crucial to protection during TB (20, 62–64).
Given that type I IFN induced IL-10 inM. tuberculosis–infected
macrophages, we assessed whether IL-10 was mediating the in-
hibitory effects of type I IFN on IL-12p40, TNF-a, and IL-1b.
IFN-b treatment of IL-10–deficient macrophages infected with
M. tuberculosis revealed that IL-10 did indeed mediate much of the
suppressive action of type I IFN on IL-12p40 production and was
totally responsible for inhibition of TNF-a production. Low levels
of TNF-a and IL-12 in the lungs of M. tuberculosis–infected mice
have previously been associated with high type I IFN levels, al-
though a role for IL-10 was not formally investigated (18).
However, IL-10 appears to limit IL-12 production during myco-
bacterial infection (38) and also limits the Th1 response and as-
sociated IFN-g production during M. tuberculosis infection in
mice (39). These results suggest that IL-10 may be an important
intermediary in type I IFN–mediated disruption of the Th1 re-
sponse during M. tuberculosis infection through suppression of
macrophage production of cytokines such as IL-12. IL-10 also
partially mediated suppression of IL-1b production by M. tuber-
culosis–infected macrophages, in agreement with a recent study
(20), but suggests that most of inhibition of IL-1b production by
type I IFN inM. tuberculosis–infected macrophages is through IL-
10–independent mechanisms. Analysis of Nos2-deficient macro-
phages suggested that iNOS is a significant mechanism additional
to IL-10 through which type I IFN mediates its suppressive effects
on IL-1b synthesis. Interestingly, in the context of IFN-g treat-
ment, iNOS was also found to negatively regulate production of
other cytokines, including IL-12 and IL-27.
We noted that even in the absence of the negative regulation of
type I IFN or IL-10, M. tuberculosis–infected macrophages rarely
produced robustly detectable levels of the biologically active form
of IL-12, IL-12p70. This suggested that IL-12p70 is under tight
regulation by other factors and/or might require additional pro-
moting signals for its induction in M. tuberculosis–infected
macrophages. IFN-g is known as an inducer of IL-12p70 (51, 53,
56) and as a crucial activator of macrophages during M. tuber-
culosis infection (5, 11, 12, 14). We therefore assessed the effects
of IFN-g stimulation on M. tuberculosis–infected macrophages
and whether type I IFN (either autocrine or exogenous) could
perturb macrophage responsiveness to IFN-g. IFN-g treatment
enhanced IL-12p40 and TNF-a production while suppressing
IL-10 and IL-1b in M. tuberculosis–infected macrophages.
However, little to no IL-12p70 was induced by IFN-g in WT
macrophages infected withM. tuberculosis. Only in the absence of
either type I IFN signaling or IL-10 could IFN-g addition induce
robustly detectable amounts of IL-12p70. This indicates that these
two pathways act as important regulators of the macrophage re-
sponse to IFN-g duringM. tuberculosis infection. In particular, the
ability of IFN-g to drive macrophage production of biologically
active IL-12p70 in response to M. tuberculosis remains compro-
mised when the type I IFN or IL-10 pathways are intact.
To mimic a situation in which an M. tuberculosis–infected
macrophage responds to both type I IFN and IFN-g present in the
microenvironment, we infected macrophages with M. tuberculosis
and concomitantly added type I IFN and IFN-g. Strikingly, type I
IFN completely abrogated the ability of IFN-g to downregulate
IL-10 production and enhance IL-12p40 and TNF-a production.
Type I IFN therefore seems to play a dominant regulatory role in
M. tuberculosis–infected macrophages, which IFN-g is unable to
overcome. How type I IFN blocks macrophage responsiveness to
IFN-g remains unclear. Type I IFN can downregulate IFN-g re-
ceptor expression (43, 54) and inhibit signaling (75) to limit
macrophage activation. In our system this mechanism is likely to
be only partially active, because type I IFN did not block all
effects of IFN-g on macrophages and only partially mediated
effects on Ifngr1 transcript levels. In particular, the ability of
IFN-g to suppress IL-1b production was largely unaffected by
IFN-b treatment, and if anything was actually increased by the
presence of IFN-b. This suggests that the effects of type I IFN on
macrophage IFN-g responsiveness are specific, rather than global.
Myeloid cells such as macrophages are known to be primary
reservoirs of M. tuberculosis bacteria during TB (1–3). A critical
role of IFN-g is therefore to activate these cells to restrict intra-
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cellular bacterial growth through induction of antimicrobial
effectors such as iNOS (5, 6, 12, 14). Our data suggest that type I
IFN signaling has inhibitory effects on IFN-g–induced macro-
phage restriction of M. tuberculosis. The mechanism for this
remains unclear but may involve inhibition of reactive oxygen
species induction (76).
In summary, we show in the present study that type I IFN is
a powerful negative regulator of the immune response to M. tu-
berculosis at the level of the infected macrophage. Type I IFN
suppresses both initial proinflammatory cytokine production by
infected macrophages, in large part through induction of high
levels of IL-10, and also strongly inhibits the macrophage’s ability
to respond to IFN-g stimulation. Type I IFN may therefore act to
interrupt the Th1 immune response, which is crucial to host re-
sistance to M. tuberculosis, through suppressing production of the
proinflammatory cytokines that prime this response but also
through making macrophages unresponsive to subsequent IFN-g
feedback from Th1 cells and other IFN-g sources. Additionally,
type I IFN may act directly to prevent IFN-g–mediated M. tu-
berculosis growth restriction by macrophages, allowing a niche
of M. tuberculosis permissive cells to develop.
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